Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation

Bibliography

• VAUGHAN WILLIAMS EM: A classification ofanti-arrhythmic actions reassessed after a decade of new drugs. J. Clin. Pharmacol. (1984) 24(4):129–147.
   PubMed Web of Science ®Google Scholar
• GWILT M, ARROWSMITH JE, BLACKBURN KJ et al.:UK-68,798: a novel, potent and highly selective class III anti-arrhythmic agent which blocks potassium channels in cardiac cells. J. Pharmacol Exp. Ther. (1991) 256 (1):318–324.
   PubMed Web of Science ®Google Scholar
• JURKIEWICZ NK, SANGUINETTI MC: Rate-dependentprolongation of cardiac action potentials by a methanesulfonanilide class III anti-arrhythmic agent. Specific block of rapidly activating delayed rectifier current by dofetilide. Circ. Res. (1993) 72 (1):75–83.
   Google Scholar
• SEDGWICK ML, RASMUSSEN HS, COBBE SM: Clinical andelectrophysiologic effects of iv. dofetilide (UK-68,798), a new class III anti-arrhythmic drug, in patients with angina pectoris. Am. J. Cardiol (1992) 69(5):513–517.
   Google Scholar
• RASMUSSEN HS, ALLEN MJ, BLACKBURN KJ, BUTROUSGS, DALRYMPLE HW: Dofetilide, a novel class III anti-arrhythmic agent. J. Cardiovasc. Pharmacol. (1992) 20 (Suppl. 2):596–105.
   Google Scholar
• TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN PE etal: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investiga-tions of Arrhythmia and Mortality on Dofetilide Study Group. N Engl. J. Med. (1999) 341 (12):857–865.
   Google Scholar
• GREENBAUM RA, CAMPBELL TJ, CHANNER KS et al:Conversion of Atrial Fibrillation and Maintenance of Sinus Rhythm by Dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research of Atrial Fibrillation Dofetilide) Study. Circulation (1998) (Suppl. 17):1-633-I–633.
   Google Scholar
• SINGH SN, BERK MR, YELLEN LG et al.: Oral dofetilide forconversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: A multicenter study. J. Am. Coll. Cardiol. (1998) 31 (2 (Suppl. A)):369A–369A.
   Google Scholar
• WARD KJ, GILL JS: Dofetilide: first of a new generationof class III agents. Exp. Opin. Invest. Drugs (1997) 6(9):1269–1281.
   PubMedGoogle Scholar
• KONINGS KT, KIRCHHOF CJ, SMEETS JR, WELLENS HJ,PENN OC, ALLESSIE MA: High-density mapping of electrically induced atrial fibrillation in humans. Circulation (1994) 89 (4):1665–1680.
   PubMed Web of Science ®Google Scholar
• ANTZELEVITCH C, SICOURI S: Clinical relevance ofcardiac arrhythmias generated by afterdepolariza-tions. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J. Am. Coll. Cardiol. (1994) 23(1):259–277.
   Google Scholar
• HOHNLOSER SH, SINGH BN: Proarrhythmia with classIII anti-arrhythmic drugs: definition, electrophysiol-ogic mechanisms, incidence, predisposing factors and clinical implications. J. Cardiovasc. Electrophysiol (1995) 6(10 Pt 2):920–936.
   Google Scholar
• ANTZELEVITCH C, SUN ZQ, ZHANG ZQ, YAN GX: Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. j. Am. Coll. Cardiol. (1996) 28(7):1836–1848.
   PubMed Web of Science ®Google Scholar
• EL SHERIF N, TURITTO G: The long QT syndrome and torsade de pointes. Pacing Clin. Electrophysiol. (1999) 22(1 Pt 1):91–110.
   Google Scholar
• ACKERMAN MJ: The long QT syndrome: ion channel diseases of the heart. Mayo Clin. Proc. (1998) 73 (3):250–269.
   PubMed Web of Science ®Google Scholar
• Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarc-tion: rationale, design and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality on Dofetilide. Clin. Cardiol (1997) 20(8):704–710.
   Google Scholar
• SMITH DA, RASMUSSEN HS, STOPHER DA, WALKER DK: Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiodca (1992) 22 (6):709–719.
   PubMed Web of Science ®Google Scholar
• LE COZ F, FUNCK-BRENTANO C, MORELL T, GHADANFAR MM, JAILLON P: Pharmacokinetic and pharmacody-namic modeling of the effects of oral and iv. admini-strations of dofetilide on ventricular repolarization. Clin. Pharmacol. Ther. (1995) 57(5):533–542.
   PubMed Web of Science ®Google Scholar
• GEMMILL JD, HOWIE CA, MEREDITH PA et al.: A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers. Br. J. Clin. Pharmacol. (1991) 3 2 (4)429–432.
   Google Scholar
• WALKER DK, ALABASTER CT, CONGRAVE GS et al.: Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab. Dispos. (1996) 2 4 (4):447–455.
   Google Scholar
• TWEEDIE D, HENDERSON C, KANE K: Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts. Eur. Pharmacol. (1993) 240(2-3):251–257.
   PubMed Web of Science ®Google Scholar
• ANDERSEN HR, WIGGERS H, KNUDSEN LL et al.: Dofetilide reduces the incidence of ventricular fibrilla-tion during acute myocardial ischaemia. A random-ised study in pigs. Cardiovasc. Res. (1994) 28(10:1635–1640.
   PubMedGoogle Scholar
• KNILANS TK, LATHROP DA, NANASI PP, SCHVVARTZ A, VARRO A: Rate and concentration-dependent effects of UK-68,798, a potent new class III anti-arrhythmic, on canine Purkinje fibre action potential duration and Br. J. Pharmacol. (1991) 103 (2):1568–1572.
   Google Scholar
• BAUER A, BECKER R, FREIGANG KD et al.: Rate- and site-dependent effects of propafenone, dofetilide, and the new I(Ks)-blocking agent chromanol 293b on individual muscle layers of the intact canine heart. Circulation (1999) 100 (21):2184–2190.
   PubMed Web of Science ®Google Scholar
• SEDGWICK ML, RASMUSSEN HS, COBBE SM: Effects of the class III anti-arrhythmic drug dofetilide on ventricular monophasic action potential duration and QTinterval dispersion in stable angina pectoris. Am. J. Cardiol. (1992) 70(18):1432–1437.
   PubMed Web of Science ®Google Scholar
• DEMOLIS JL, FUNCK BC, ROPERS J, GHADANFAR M, NICHOLS DJ, JAILLON P: Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation (1996) 94(7):1592–1599.
   PubMed Web of Science ®Google Scholar
• KOBER L, THE DIAMOND STUDY GROUP: A Clinical Trial of Dofetilide in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction. The DIAMOND MI Study. Circulation (1998) 98 (Suppl.
   Google Scholar
• GREENBAUM RA, CAMPBELL TJ, CHANNER KS et al.: Oraldofetilide improves quality of life: An EMERALD substudy. Circulation (1999) 100 (Suppl. 18)1-286-I–286.
   Google Scholar
• PRITCHETT EL, WILKINSON WE: Effect of dofetilide on survival in patients with supraventricular arrhyth-mias. Am. Heart J. (1999) 138(5 Pt 1):994–997.
   Google Scholar
• DEEDWANIA PC, SINGH BN, ELLENBOGEN K, FISHER S, FLETCHER, SINGH SN: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of anti-arrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation (1998) 98 (23):2574–2579. Christian Torp-Pedersent, Bente Brendorp & Lars Kober
   Google Scholar